News – Page 3 – Alligator Bioscience

2019-04-11

Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bi ...

2019-04-10

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2019-04-10

Regulatory

Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...

2019-04-02

Regulatory

Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...

2019-03-22

Regulatory

Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2019-03-18

Regulatory

Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...

2019-03-07

Regulatory

Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...

2019-02-14

Regulatory

The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...

2019-02-12

Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report ...